The potency of the inhibitory effect of NCT-50 on the viability of NSCLC cells and Hsp90 function were comparable or superior to that of previously developed deguelin analogs, novobiocin and its analogs, and Hsp90 inhibitors in clinical trials22–24,26,28,30, emphasizing the potential of NCT-50 as a novel and efficacious Hsp90 inhibitor. The gene discussed is HSP90AA1; the disease is non-small cell lung carcinoma.